LipoMedics to present new data at three upcoming international conferences related to development of injectable Paclitaxel, phospholipid bound nanoparticle formulation
Press Release
By:
Ref: Yahoo!Finance
Published: 10/25/2016
Photo - http://photos.prnewswire.com/prnh/20161024/431589
Paclitaxel is a highly effective chemotherapeutic drug which disrupts the ability of cancer cells to divide and thus cease the growth or spread of tumors. It is being successfully used to treat mainly breast, lung and ovarian cancers but its water insoluble nature creates challenges.
To overcome these challenges, scientists at LipoMedics have studied and optimized different parameters of a one-pot synthesis process. Results will be presented detailing the synthesis procedure and formulation characteristics such as size, drug incorporation, and stability. Additional processes such as lyophilization were also optimized for commercial scale production. This data will be presented at the Nanoparticle Therapeutics 2016, 23rd - 26th October, 2016 in Australia and the BIT's 6th Annual Symposium of Drug Delivery Systems, 16th -19th November, 2016 in China.
Electrochemical characterization of LM-102, LM-101 (phosphatidylcholine 10 and lyso-phosphatidylcholine 10 stabilized Paclitaxel formulation) and generic-Abraxane nanoformulations were also conducted to study/understand differences observed in voltammetry scans and capacitance which for in process and release testing of these pharmaceuticals. This data will be presented at the 2016 AAPS Annual Meeting and Exposition, 13th -17th November 2016, Denver, Colorado.
There will be a poster presentation at the Nanoparticle Therapeutics 2016 in Australia.
Conference: Nanoparticle Therapeutics 2016, 23rd - 26th October 2016
Title :"An Injectable Phospholipid-Cholesteryl Ester Nanoparticle Formulation of Paclitaxel: Influence of Lipid Composition, Drug Concentration, Storage Temperature, Lyophilization, and Additives"
Date and Time: Monday, 24th October, 2016 from 4:20 pm - 6:00 pm
Location: Pullman Palm Cove Sea Temple Resort & Spa, Queensland, Australia
Authors: Gary Williams2, Shradha Prabhulkar2, Steve Miller2, Zachary Yim1, Walter McConathy1, Tapas De1, Vuong Trieu2
There will be a poster presentation at the 2016 AAPS Annual Meeting and Exposition in Denver.
Conference:2016 AAPS Annual Meeting and Exposition, 13th -17th November 2016, Colorado, Denver
Title: "Cyclic Voltammogram of Paclitaxel Nanoparticle- Use in Development of Charge Neutral Nanoparticle (NPB)"
Date and Time: Wednesday, 16th November, 2016, 10:30 am - 11:00 am
Location: Exhibit Hall E at Colorado Convention Center, Denver, Colorado
Authors: Steve Miller2, Shradha Prabhulkar2, Gary Williams2, Dongwon Lee2, William Yeh2, Vuong Trieu1
There will be an oral presentation at the BIT's 6th annual symposium of Drug Delivery Systems 2016 in China.
Conference:BIT's 6th Annual Symposium of Drug Delivery Systems, 16th-19th November 2016
Title:"Phospholipid Bound Nanoparticles Paclitaxel as next generation Abraxane"
Theme: Smart Precise Medicine, Symposium 4: Smart Nanomedicine
Date and Time: Friday, 18th November, 2016 from 4:10 pm - 4:30 pm
Location: Nanjing, China
Author: Zachary Yim1
Institutions: 1LipoMedics Inc, 3400 Camp Bowie Blvd, Fort Worth, Texas 76107, USA
2Autotelic Inc, 940 South Coast Drive, Suite 100, Costa Mesa, CA 92626, USA
About LipoMedics Inc.
LipoMedics Inc. is developing personalized paclitaxel therapy based on our proprietary Therapeutic Drug Monitoring (TDM) device and our platform for delivery of water insoluble drugs including paclitaxel. The company's platform technology is the phospholipid paclitaxel nanoparticle that upon injection disperses paclitaxel in the plasma compartment. This paclitaxel/phospholipids formulation represents the "Next Generation of Paclitaxel Nanomedicine". More information is available at www.lipomedics.com
About Autotelic Inc.
Autotelic works through our partners to transform how medications are being delivered. The Autotelic Inc. platform is our Therapeutic Drug Monitoring (TDM) device which allows PK guided dosing, reducing the toxicity from overmedication and increasing the efficacy from under-medication. Current dosing schemes result in either too much drug exposure or too little drug exposure because of individual pharmacokinetic variations. Autotelic's pipeline includes TDM devices for management of oncology, hypertension and pain. More information is available at www.autotelicinc.com
About Paclitaxel
Paclitaxel is a hydrophobic mitotic inhibitor with a powerful anticancer effect. It belongs to the group of taxanes (together with docetaxel), which are potent cytotoxic diterpenes derived from yew trees. Paclitaxel is active against a spectrum of malignancies that are generally considered to be refractory to conventional therapy.
Forward-LookingStatements
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. We caution you that any forward-looking information provided by or on our behalf is not a guarantee of future performance. Forward-looking statements include: (I) changes in domestic and foreign economic or non-economic conditions, (II) the effect of federal, state and foreign FDA regulations, (III) Intellectual property and other claims, (IV) the effect of our clinical and non-clinical trial, (V) the impact on our branding strategy and other factors. All such forward-looking statements are current only as of the date on which such statements are made. We do not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of the companies may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. The companies above neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which differ from those anticipated.
Media Contact: Tapas De Ph.D., Cheif Executive Officer, LipoMedics Inc., 818-575-9505, info@lipomedics.com